ELElisabet Rodriguez Llorian

Elisabet Rodriguez Llorian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elisabet Rodriguez Llorian has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Larry David Lynd

    Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada

    6 shared publications
  • Amir Khakban

    Collaboration for Outcomes Research and Evaluation (CORE), Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada

    3 shared publications
  • Scott Burton Patten

    Department of Community Health Sciences, Cumming School of Medicine, University of Calgary

    3 shared publications
  • Alexandre Prat

    Department of Neurology, Faculty of Medicine, Université de Montreal, Montreal, QC, Canada

    2 shared publications
  • Anthony Traboulsee

    Division of Neurology, Department of Medicine, The University of British Columbia, Vancouver, BC, Canada

    2 shared publications
  • Gregory Mason

    Department of Economics University of Manitoba Winnipeg Canada

    2 shared publications

Latest Publications

  • Open Access

    A budget impact analysis for the addition of rare disease genes to secondary findings screening during genome-wide sequencing

    by Nicola Kopac, Nick Dragojlovic, Elisabet Rodriguez Llorian, Anna Lehman, Larry D. Lynd

  • Open Access

    Employment status, productivity loss, and associated factors among people with multiple sclerosis

    by Elisabet Rodriguez Llorian, Wei Zhang, Amir Khakban, Kristina Michaux, Scott Patten, Anthony Traboulsee, Jiwon Oh, Shannon Kolind, Alexandre Prat, Roger Tam, et al.

    Background: Multiple Sclerosis (MS) affects people in their most productive years of life. Consequently, MS can substantially affect employment and work-related outcomes. Objectives: This study characterizes productivity loss and employment status of people with multiple sclerosis (pwMS) and investigates associated factors. Methods: We used baseline data collected as part of the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo). Using the Valuation of Lost Productivity questionnaire, we measured MS-related paid work productivity loss for those employed, productivity losses incurred by those unemployed (i.e. lost employment time), and unpaid work productivity losses for all. A set of sociodemographic, disease, and performance-related factors were investigated using a two-part regression model for productivity loss and a multinomial logistic model for employment status. Results: From the cohort of 888 pwMS enrolled at baseline (mostly showing mild to moderate disability), 75% were employed, and of those unemployed, 69% attributed their unemployment to health-related issues. Total productivity loss over a 3-month period averaged 64 and 395 hours for those employed and unemployed, respectively. Some factors that affected productivity loss and employment status included use of disease-modifying therapies, fatigue, and performance indicators such as cognitive processing speed. Conclusion: Productivity loss experienced by employed and unemployed pwMS is substantial. Targeting the identified modifiable factors is likely to improve work productivity and permanence of MS patients in the workforce.


  • Direct Health Care Costs Associated With Multiple Sclerosis

    by Amir Khakban, Elisabet Rodriguez Llorian, Kristina D. Michaux, Scott B. Patten, Anthony Traboulsee, Jiwon Oh, Larry D. Lynd, on behalf of CanProCo Study Group

    Background and Objectives Multiple sclerosis (MS), a leading cause of nontraumatic neurologic disability in young adults, exerts a substantial economic burden on the health care system. The objective of this study was to quantify the excess health care costs of MS in British Columbia, Canada. Methods A retrospective-matched cohort study of patients with MS was conducted using population-based administrative health data from 2001 to 2020. Patients with MS who satisfied a validated case definition were matched to 5 unique controls without MS on sex, age, and cohort entry date. Patients and controls were followed to the end of 2020 or to their last health care resource use, whichever came first. We calculated the direct medical costs for each individual, including outpatient services use, hospital admissions, and dispensed medications. We used generalized linear models with an identity link and normal distribution to estimate the excess cost of MS as the mean cost difference between patients with MS and controls. All costs were reported in 2020 Canadian dollars. Results A total of 17,071 patients with MS were matched to 85,355 controls. Overall, 72.4% were female, and the mean age at cohort entry date was 46.1 years. The excess cost of MS was $6,881 (95% CI: $6,713, $7,049) per patient-year. Inpatient, outpatient, and medication costs accounted for 25%, 10%, and 65% of excess costs, respectively. Excess costs were higher in patients with MS with at least one disease-modifying therapy (DMT) prescription ($13,267; 95% CI: $12,992–$13,542) compared with non-DMT users ($3,469; 95% CI: $3,297–$3,641) and even higher among frequent DMT users ($24,835; 95% CI: $24,528–$25,141). Patients with MS with a history of at least one relapse requiring hospitalization had higher excess costs ($10,543; 95% CI: $10,136–$10,950) compared with patients with MS without a relapse; hospitalizations accounted for 51% of the costs in this group. The excess cost of hospitalizations was $1,391 lower among frequent DMT users than non-DMT users. Discussion The economic burden of MS is considerable, with medications, particularly DMTs, being the largest cost driver. Future studies should investigate how disease management strategies, including early diagnosis and timely use of DMTs, could offset future and ongoing costs while improving patients9 quality of life.


  • The effect of rapid exome sequencing on downstream health care utilization for infants with suspected genetic disorders in an intensive care unit

    by Elisabet Rodriguez Llorian, Nick Dragojlovic, Teresa M. Campbell, Jan M. Friedman, Horacio Osiovich, Tara Candido, Jan Christilaw, Christèle du Souich, Alison M. Elliott, Daniel M. Evans, et al.


  • Open Access

    Productivity loss among people with early multiple sclerosis: A Canadian study

    by Elisabet Rodriguez Llorian, Wei Zhang, Amir Khakban, Scott Patten, Anthony Traboulsee, Jiwon Oh, Shannon Kolind, Alexandre Prat, Roger Tam, Larry D Lynd

    Objectives: To analyze work productivity loss and costs, including absenteeism (time missed from work), presenteeism (reduced productivity while working), and unpaid work loss, among a sample of employed people with multiple sclerosis (pwMS) in Canada, as well as its association with clinical, sociodemographic, and work-related factors. Methods: We used cross-sectional data collected as part of the Canadian Prospective Cohort Study to Understand Progression in MS (CanProCo) and information from the Valuation of Lost Productivity questionnaire. Results: Among 512 pwMS who were employed, 97% showed no or mild disability and 55% experienced productivity loss due to MS in the prior 3 months. Total productivity time loss over a 3-month period averaged 60 hours (SD = 107; 23 from presenteeism, 19 from absenteeism, and 18 from unpaid work), leading to a mean cost of lost productivity of CAD$2480 (SD = 4282) per patient, with an hourly paid productivity loss greater than the wage loss. Fatigue retained significant associations with all productivity loss outcomes. Conclusion: Unpaid work loss and productivity losses exceeding those of the employee alone (due to teamwork and associated factors) are key additional contributors of the high economic burden of MS. Workplace accommodations and treatments targeted at fatigue could lessen the economic impact of MS.


  • Future trends in clinical genetics services: exploring the perspectives of Canadian genetics professionals using the Delphi method

    by Nicolas Dragojlovic, Kennedy Borle, Nicola Kopac, Elisabet Rodriguez Llorian, Jan Friedman, Alison M. Elliott, Larry Lynd

  • Electronic medical records and primary care quality: Evidence from Manitoba

    by Elisabet Rodriguez Llorian, Gregory Mason

    Improvements in quality of care through supporting decision‐making processes and increased efficiency have prompted widespread implementation of electronic medical records (EMRs) in Canada. Using a set of indicators of preventive care, chronic disease management, and hospitalizations due to ambulatory care sensitive conditions (ACSC), this study measures the effect of EMR adoption on quality of primary care measures. Population‐based data for the Canadian province of Manitoba are used in a difference‐in‐differences approach with patient‐ and time‐fixed effects. Evidence of changes in the selected quality‐of‐care indicators is weak, with preventive care, management of asthma, and hospitalizations showing no significant change due to EMR adoption. A statistically significant increase in the quality of diabetes care was found for EMR users, changes being larger for late EMR adopters which is possibly explained by a network effect. This research demonstrates that measuring whether EMRs prompt changes in the quality of care confronts serious challenges. The rapid evolution and gradual adoption of EMR technology, the inevitable learning/acceptance process by individual health practitioners, and its potential reflection on different patient populations create unmeasurable variables that confound EMRs' impact. This study also underscores the importance of data development to support the economic value of EMRs.


  • Healthcare utilization and telemedicine: An evaluation using linked administrative data from Manitoba

    by Elisabet Rodriguez Llorian, Gregory Mason

    This research examines utilization patterns for patients using telemedicine compared to those receiving treatment conventionally. Administrative data from 2007–2016 is linked to records from the Manitoba Telehealth programme to conduct a population-level study. Using a high dimensional propensity-weighted regression model, the study compares four utilization measures between telemedicine users and non-users. These include: ambulatory visits (number of visits to any physician), visits to primary care physicians, visits to specialists and the number of hospitalizations. Compared to non-users, telemedicine patients showed a higher number of in-person visits. Specifically, using incidence-rate ratios, telemedicine users had 1.32 more ambulatory visits (p < 0.001; 95% confidence interval, 1.23–1.41), 1.26 more visits to primary care practitioners (pp < 0.001; 95% confidence interval, 1.19–1.61) and 1.14 more hospitalizations (p>0.1; 95% confidence interval, 0.91–1.43). These results were robust to restricted analyses for distance, regions, and chronic conditions. Those patients with frequent virtual encounters with a specialist showed a decrease of the frequency of in-person visits of the same type of care (incidence-rate ratio=0.48, p < 0.001; 95% confidence interval, 0.44–0.54). Patterns in utilization vary between telemedicine users and non-users, with users showing a higher number of in-person visits than non-users, and only frequent users of telemedicine showing reduced in-person visits. Future investigation linking utilization patterns with patient care outcomes and costs will inform healthcare policy and clinical treatment plans.


  • Open Access

    Data on medical technology: A new set of variables

    by Elisabet Rodriguez Llorian, Janelle Mann